TickerGuard
Buy Day today: Poor (44) Weak market breadth · major macro event coming up
SMMT

Summit Therapeutics PLC

Healthcare · Biotechnology

16.50$ -3.9% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Cash Flow

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Cash Flow SMMT
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
-878.6% -1,910.3% 638.7% -145.3% -61.5% -62.0% -5,619.2% -2,974.4% -5,812.4%
2.6% 5.3% 3.1% 4.0% 3.4% 3.2% 233.9% 100.6% 176.5%
76.7% 129.0% 72.5% 16.1% 11.0% 1.3% 206.3% 524.7% 1,670.1%
117.4% 169.2% 68.3% 2.1% 6.2% 10.4% 729.2% 753.3% 4,470.2%
-39.5% 82.3% 1,674.6% 48.9% -96.1% 2.2% 72.3% -2.7% 1,379.2%
2.8% 7.3% 4.6% 4.8% 0.3% 0.6% 49.2% 12.5% 87.2%
1.3% -4.0% -4.2% -52.4% -0.6% -0.3% -49.2% -12.5% -87.2%
0.0% 0.0% 0.0% 0.0%
1,634.3% 78,064,012,490,242.0% 42,087,542,087,542.1% 7,058,159,232,072.3% 0.0%
-16.7% 1.8% 1.0% -0.9% -0.5% -0.8% 82,687.3% 28,745.2% 89,164.8%
1,614.3% 2,461.0% 21.7% 137.4% 78.0% 77.0% 5,904.2% 3,192.8% 86,699.0%
737.0% 560.2% 618.6% -79.5% 11.8% 15.7% 300.8% 220.2% 80,628.5%
-881.4% -1,917.6% 634.1% -150.0% -61.8% -36.8% -5,668.4% -2,986.9% -5,899.6%

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?